Assembly Biosciences Inc (ASMB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Assembly Biosciences Inc (ASMB) has a cash flow conversion efficiency ratio of -0.111x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.10 Million) by net assets ($198.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Assembly Biosciences Inc to measure how many days the company can operate on defensive assets alone.
Assembly Biosciences Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Assembly Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Assembly Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Assembly Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EUROKAI GmbH & Co. KGaA
F:EUK3
|
0.017x |
|
Fine Semitech Corp
KQ:036810
|
-0.021x |
|
Zhejiang Dibay Electric Co Ltd
SHG:603320
|
0.023x |
|
Alltek Technology Corp
TW:3209
|
0.018x |
|
Qingdao Vland Biotech Co Ltd
SHG:603739
|
0.013x |
|
International Money Express Inc
NASDAQ:IMXI
|
-0.123x |
|
Brainsway Ltd
TA:BWAY
|
0.020x |
|
Sandhar Technologies Limited
NSE:SANDHAR
|
0.069x |
Annual Cash Flow Conversion Efficiency for Assembly Biosciences Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Assembly Biosciences Inc from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Assembly Biosciences Inc (ASMB) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $206.75 Million | $-41.09 Million | -0.199x | +87.03% |
| 2024-12-31 | $33.36 Million | $-51.12 Million | -1.532x | -376.89% |
| 2023-12-31 | $41.10 Million | $22.74 Million | 0.553x | +154.16% |
| 2022-12-31 | $82.66 Million | $-84.46 Million | -1.022x | -84.81% |
| 2021-12-31 | $168.93 Million | $-93.40 Million | -0.553x | -111.27% |
| 2020-12-31 | $240.58 Million | $-62.96 Million | -0.262x | +14.95% |
| 2019-12-31 | $273.22 Million | $-84.07 Million | -0.308x | +0.22% |
| 2018-12-31 | $210.65 Million | $-64.96 Million | -0.308x | -1975.30% |
| 2017-12-31 | $113.12 Million | $1.86 Million | 0.016x | +103.77% |
| 2016-12-31 | $79.88 Million | $-34.88 Million | -0.437x | -177.33% |
| 2015-12-31 | $118.74 Million | $-18.70 Million | -0.157x | +38.41% |
| 2014-12-31 | $58.57 Million | $-14.97 Million | -0.256x | +64.81% |
| 2013-12-31 | $24.49 Million | $-17.80 Million | -0.727x | +39.48% |
| 2012-12-31 | $17.81 Million | $-21.38 Million | -1.200x | -65.36% |
| 2011-12-31 | $34.53 Million | $-25.07 Million | -0.726x | -61.86% |
| 2010-12-31 | $11.63 Million | $-5.21 Million | -0.449x | -272.03% |
| 2009-12-31 | $-13.36 Million | $-3.48 Million | 0.261x | -40.55% |
| 2008-12-31 | $-9.46 Million | $-4.15 Million | 0.439x | -- |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase … Read more